Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 8 clinical trials
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).

  • 30 Jan, 2021
  • 15 locations
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the

  • 28 Jan, 2021
  • 1 location
Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

This is a multicenter, open-label Phase 1/2 study of DCC-3014 in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose

solid neoplasm
solid tumor
measurable disease
  • 18 Jun, 2021
  • 24 locations
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

AMB-051-01 is a multicenter study with an adaptive design that will enroll approximately 12 subjects with TGCT of the knee for 12 weeks of multiple-dose, open-label treatment with AMB-05X.

  • 19 Jul, 2021
  • 6 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

>Desmoid tumors Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) Malignant giant cell tumors Chordoma (closed to accrual 11/29/2018)

pancreatic adenocarcinoma
solid tumour
gilbert's disease
  • 24 Sep, 2021
  • 818 locations
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of patients with TGCT.

  • 18 Jul, 2021
  • 5 locations
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer Anaplastic Thyroid Cancer Osteosarcoma or Other Bone and Soft Tissue Sarcomas

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by …

biologic agent
cancer chemotherapy
platelet count
  • 02 Jul, 2021
  • 2 locations
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO (Pexidartinib) Treatment

A study to evaluate the long-term risk of hepatic failure with TURALIO (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO (pexidartinib) and experience hepatotoxicity.

  • 20 Apr, 2021
  • 3 locations